In late August 2021, the acquisition of Aldervon by Danaher for $10B was finally consummated. With Aldevron in the business of high-quality plasmid DNA production for a wide range of research, preclinical, clinical, and diagnostic applications, two years earlier (in 2019) the small firm had been the subject of a leveraged buyout by EQT - a Swedish firm that invests in good companies across the world with a mission to help them develop into great and sustainable companies. Headquartered in Fargo ND, with facilities in Madison WI and Freiburg, Germany, Aldevron, LLC specialized in production of antibodies, proteins, nucleic acids, plasmids, and genomic DNA products. At its founding, a small lab with ties to North Dakota State University (NDSU), the much expanded firm now produces and purifies plasmid DNA for research, preclinical, clinical, and diagnostic applications, as well as phase I DNA vaccine and therapeutic gene transfer studies; GMP manufacturing; and is used as molecular diagnostic controls. The company also offers plasmid production products, including DNA vaccine plasmids, gWiz reporter plasmids, UMVC expression and reporter vectors, UMVC retroviral vectors, UMVC mouse and human cytokine vectors, adenoviral vectors, and genetic immunization and antibody products. In addition, Aldevron offers custom manufacturing services that include OEM vector production; process, formulation, and product development; competent cell production; protein and nucleic acid molecular weight marking; buffer production, packaging, and labeling; production of clinical diagnostics; fill, labeling, packaging, and assembly; and qualified reagents. Further, the company provides storage distribution stability services, gene synthesis, and antibody processing and sequencing services serving clients in the United States and internationally.
